Ipsen Executive and Leadership Team

Gonzalo Colimodio, the Chief Financial Officer at Ipsen, directs the company's financial strategy and operations. This leadership role involves managing all fiscal activities, including budgeting, forecasting, and financial reporting, ensuring robust financial health for the biopharmaceutical group. Colimodio oversees the allocation of capital to support research and development initiatives in oncology, neuroscience, and rare diseases, aligning financial resources with strategic growth objectives. The Chief Financial Officer's oversight extends to investor relations and maintaining strong relationships with financial stakeholders, crucial for securing investment and driving long-term value. By optimizing financial performance, Gonzalo Colimodio directly contributes to Ipsen's mission of delivering innovative treatments to patients worldwide. This executive's focus ensures fiscal discipline and supports the expansion of the company's specialty care portfolio across key global markets.

Andrew Singer, the Executive Vice President & Chief Financial Officer at Ipsen, provides critical financial leadership and strategic direction for the global biopharmaceutical group. This senior role encompasses the comprehensive management of Ipsen's financial architecture, including capital allocation, financial planning, and risk management, supporting the company's focus on oncology, neuroscience, and rare diseases. Singer's oversight ensures that financial operations are optimized to fuel innovation and commercial success across key therapeutic areas. The Executive Vice President & Chief Financial Officer's influence extends to shaping corporate financial policy and driving efficiency throughout the organization. By guiding financial strategy, Andrew Singer plays a vital part in enhancing shareholder value and enabling the development and delivery of life-changing specialty care medicines. This executive's expertise underpins Ipsen's sustained growth and market position.

Koceir Hichem, the Chief Marketing Officer, Quality at Ipsen, spearheads the strategic marketing initiatives and ensures the highest standards of quality across the organization. This dual focus involves developing and executing comprehensive marketing plans for Ipsen's specialty care medicines in oncology, neuroscience, and rare diseases, driving market penetration and patient access. Hichem's responsibilities include overseeing quality assurance and control processes, guaranteeing that all products meet stringent regulatory and safety requirements. The Chief Marketing Officer, Quality's role is pivotal in translating scientific innovation into commercially successful therapies, fostering strong brand recognition and market leadership. By integrating marketing acumen with a rigorous quality framework, Koceir Hichem ensures that Ipsen delivers both effective treatments and maintains unwavering product integrity. This executive's leadership supports the company's global reach and commitment to patient well-being.

Farida Bouziane, the Chief Marketing Officer & Manager, Quality Snior & , Africa (North) at Ipsen, directs marketing strategies and quality management within the North African region, alongside broader organizational quality oversight. This executive's mandate involves tailoring Ipsen's specialty care offerings in oncology, neuroscience, and rare diseases to meet the specific needs of the North African market, driving commercial success and patient access. Bouziane's leadership ensures adherence to stringent quality standards, guaranteeing the integrity and efficacy of Ipsen's pharmaceutical products in the region and beyond. The Chief Marketing Officer & Manager, Quality Snior & , Africa (North)'s role is essential for expanding Ipsen's footprint and impact in diverse geographies. By combining regional marketing expertise with a deep commitment to quality, Farida Bouziane strengthens Ipsen's reputation and operational excellence. This executive's focus supports the company's global mission to improve patient lives through innovative treatments.